IKNA
Ikena Oncology, Inc. [IKNA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
IKNA Stock Summary
Top IKNA Correlated Resources
IKNA
Top 10 Correlated ETFs
IKNA
Top 10 Correlated Stocks
IKNA
In the News
IKNA Financial details
Company Rating
-
Market Cap
64.18M
Income
-66.87M
Revenue
9.16M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
43
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-1.4
Forward P/E
-
PEG
1.12
P/S
6.74
P/B
0.55
P/C
-
P/FCF
-1.24
Quick Ratio
10.22
Current Ratio
10.41
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.61
EPS next Y
-
EPS next Q
-
EPS this Y
-11.41%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
28.24%
Revenue last 5Y
-7.81%
Revenue Q/Q
-44.39%
EPS Q/Q
2.5%
-
-
-
-
SMA20
-17.16%
SMA50
-23.97%
SMA100
-35.09%
Inst Own
-
Inst Trans
-
ROA
-28%
ROE
-41%
ROC
-0.35%
Gross Margin
100%
Oper. Margin
-492%
Profit Margin
-433%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.02-7.64
52W High
-83.71%
52W Low
+14%
RSI
42.25
Rel Volume
0.24
Avg Volume
429.16K
Volume
105.06K
Perf Week
3.64%
Perf Month
-20.83%
Perf Quarter
-33.33%
Perf Half Y
-32.54%
-
-
-
-
Beta
0.332
-
-
Volatility
0.03%, 0.11%
Prev Close
2.7%
Price
1.14
Change
0%
Company Profile
- Volume Average 429.16K
- Market Capitalization 64.18M
- Employee 43
- CEO Dr. Mark Manfredi Ph.D.
- Headquarters Boston,MA,US
- IPO Date 2021-03-26
-
Website
https://ikenaoncology.com 
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
